Synaptogenix announces live appearance of its president and cso on streaming financial news network

New york, june 24, 2021 /prnewswire/ -- synaptogenix, inc. (nasdaq: snpx), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that dr. daniel alkon, the company's president and chief scientific officer, will appear as a featured guest on td ameritrade network's "the watch list" on friday, june 25, 2021 at 1:20pm et (www.tdameritradenetwork.com).   dr. alkon will discuss the progression of treatments for alzheimer's disease ("ad"), the regenerative mechanism of action for synaptogenix's lead drug, bryostatin-1, and how the recently approved drug from biogen may impact future treatments in the ad space.
SNPX Ratings Summary
SNPX Quant Ranking